BFNH BIOFORCE NANOSCIENCES HOLDINGS, INC.
Laboratory Analytical Instruments · OTC · SEC CIK 1310488 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY75.0%
TTM EPS YoY80.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-44.3%
ROA-28.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.23x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.39x
Accruals ratio-17.7%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| SG&A expense | $307,930 | $118,580 | $11,983 | $12,048 | $10,165 | $17,031 | $27,707 | $17,410 |
| Operating income | — | — | — | — | -$115,915 | -$122,781 | -$133,457 | — |
| Pretax income | -$341,680 | -$262,330 | -$117,733 | -$117,798 | -$115,915 | -$122,781 | -$133,457 | — |
| Net income | -$341,680 | $238,682 | -$102,411 | -$118,605 | -$115,915 | -$122,781 | -$935,457 | -$123,160 |
| EPS (basic) | -0.01 | 0.01 | 0.00 | — | 0.00 | 0.00 | -0.03 | — |
| EPS (diluted) | -0.01 | 0.01 | 0.00 | — | 0.00 | 0.00 | -0.03 | — |
| Weighted avg. shares (diluted) | 35.04M | 33.54M | 33.52M | — | 33.52M | 33.52M | 32.25M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $31,696 | $307 | $6,347 | $786 | $784 | $905 | $13,799 | $862 |
| Current assets | $2.00M | $2.15M | $6,347 | $786 | $784 | $905 | $13,799 | $862 |
| Total assets | $2.24M | $2.39M | $6,347 | $786 | $784 | $905 | $13,799 | $862 |
| Current liabilities | $277,033 | $84,767 | $727,301 | $619,329 | $500,722 | $384,928 | $275,041 | $2.30M |
| Total liabilities | $277,033 | $84,767 | $727,301 | $619,329 | $500,722 | $384,928 | $275,041 | $2.30M |
| Shareholders' equity | $1.96M | $2.30M | -$720,954 | -$618,543 | -$499,938 | -$384,023 | -$261,242 | -$2.30M |
| Shares outstanding | 38.07M | 33.55M | 33.52M | 33.52M | 33.52M | 33.52M | 33.52M | 29.27M |
| Cash flow statement | ||||||||
| Operating cash flow | -$94,790 | -$26,980 | $7,088 | -$10,921 | -$11,121 | -$27,893 | -$15,215 | -$14,835 |
| Financing cash flow | $126,179 | $20,940 | -$1,527 | $10,923 | $11,000 | $14,999 | $28,152 | $14,062 |
Free plan shows the latest 8 periods; Pro shows all 37 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.